1.17

13.59% 0.14

Alx Oncology Holdings Inc (ALXO)

Overview News Price History Option Chain Financials Discussions Forecast

Alx Oncology Holdings Inc stock is traded at $1.17, with a volume of 2.86M. It is up +13.59% in the last 24 hours and up +143.80% over the past month. ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Previous Close:

$1.03

Open:

$1.05

24h Volume:

2.86M

Relative Volume:

3.70

Market Cap:

$62.65M

Revenue:

Net Income/Loss:

$-151.16M

P/E Ratio:

-0.3939

EPS:

-2.97

Net Cash Flow:

$-130.08M

1W Performance:

+81.59%

1M Performance:

+143.80%

6M Performance:

+4.46%

1Y Performance:

-49.79%

1-Day Range:

$1.03

$1.19

1-Week Range:

$0.6601

$1.19

52-Week Range:

$0.404

$2.585

Alx Oncology Holdings Inc Stock (ALXO) Company Profile

Name

Alx Oncology Holdings Inc

Sector

Healthcare (1157)

Industry

Biotechnology (645)

Phone

650-466-7125

Address

323 ALLERTON AVENUE, SOUTH SAN FRANCISCO

Employee

Twitter

Next Earnings Date

2024-11-11

Latest SEC Filings

ALXO's Discussions on Twitter

Compare ALXO with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ALXO Alx Oncology Holdings Inc	1.17	51.99M	0	-151.16M	-130.08M	-2.97
VRTX Vertex Pharmaceuticals Inc	395.12	99.96B	11.39B	3.64B	3.50B	13.99
REGN Regeneron Pharmaceuticals Inc	589.48	60.83B	14.21B	4.46B	3.56B	39.68
ALNY Alnylam Pharmaceuticals Inc	454.38	59.89B	2.46B	-319.09M	-52.09M	-2.47
ARGX Argen X Se Adr	660.00	40.47B	3.06B	1.28B	447.35M	21.30
ONC Beone Medicines Ltd Adr	313.67	37.96B	3.81B	-644.79M	-669.77M	-6.24

Alx Oncology Holdings Inc Stock (ALXO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-06-25	Upgrade	Jefferies	Hold → Buy
Dec-19-24	Downgrade	Jefferies	Buy → Hold
Mar-08-24	Downgrade	Stifel	Buy → Hold
Dec-08-23	Upgrade	Jefferies	Hold → Buy
Dec-22-21	Downgrade	Jefferies	Buy → Hold
Sep-30-21	Initiated	Stifel	Buy
May-05-21	Resumed	Credit Suisse	Outperform
Apr-26-21	Resumed	Credit Suisse	Outperform
Apr-06-21	Initiated	UBS	Buy
Feb-10-21	Initiated	H.C. Wainwright	Buy
Aug-11-20	Initiated	Cantor Fitzgerald	Overweight
Aug-11-20	Initiated	Credit Suisse	Outperform
Aug-11-20	Initiated	Jefferies	Buy
Aug-11-20	Initiated	Piper Sandler	Overweight

View All

Alx Oncology Holdings Inc Stock (ALXO) Latest News

Aug 20, 2025

Recovery Signals Appearing in ALX Oncology Holdings Inc. ChartsJuly 2025 Outlook & Real-Time Buy Signal Alerts - thegnnews.com

Aug 20, 2025

Published on: 2025-08-21 00:59:20 - mustnews.co.kr

Aug 20, 2025

Aug 19, 2025

ALX Oncology doses first patient in phase 1 trial of EGFR cancer drug - Investing.com Nigeria

Aug 19, 2025

ALX Oncology Holdings Inc.’s Price Action Aligns with Quant SignalsJuly 2025 Big Picture & Long-Term Growth Portfolio Plans - beatles.ru

Aug 19, 2025

ALX Oncology shares fall 11.43% intraday despite dosing first patient in Phase 1 trial. - AInvest

Aug 19, 2025

ALX Oncology Doses First Patient in Phase 1 Dose Escalation - GlobeNewswire

Aug 19, 2025

First-in-Class EGFR Cancer Drug: ALX Oncology Launches Groundbreaking Phase 1 Trial for Solid Tumors - Stock Titan

Aug 19, 2025

Volume Surge May Signal Institutional Interest in ALX Oncology Holdings Inc.Trade Risk Summary & Low Risk High Reward Trade Ideas - sundaytimes.kr

Aug 14, 2025

Healthcare Stocks Move in After-Market Session - AInvest

Aug 14, 2025

Aug 13, 2025

ALX Oncology shares fall 1.51% after-hours following Q2 2025 earnings call and investor presentation. - AInvest

Aug 13, 2025

Peninsula biotech company sets two clinical trials to revive its cancer-fighting fortunes - The Business Journals

Aug 13, 2025

ALX Oncology Holdings Inc. (NASDAQ:ALXO) Q2 2025 Earnings Call Transcript - Insider Monkey

Aug 13, 2025

ALX Oncology Q2 2025 Earnings Call Transcript - MarketBeat

Aug 13, 2025

ALX Oncology shares rise 6.34% premarket after positive Q2 2025 results and clinical trial updates. - AInvest

Aug 13, 2025

ALX Oncology Holdings Inc Reports Promising Trial Results and Pipeline Progress - AInvest

Aug 13, 2025